Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh

被引:29
|
作者
Alam, Shahinul [1 ]
Noor-E-Alam, Sheikh Mohammad [1 ]
Chowdhury, Ziaur Rahman [1 ]
Alam, Mahabubul [1 ]
Kabir, Jahangir [1 ]
机构
[1] Bangabandhu Sheikh Mujib Med Univ, Dept Hepatol, Dhaka 1000, Bangladesh
关键词
Fatty liver; Gamma-glutamyl transpeptidase; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Alanine aminotransferase; Obesity; Basal metabolic index;
D O I
10.4254/wjh.v5.i5.281
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To explore the prevalence and risk factors for nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) patients. METHODS: We have included 493 patients with sonographic evidence of a fatty change, and 177 of these individuals were evaluated and confirmed after liver biopsy. The exclusion criteria consisted of significant alcohol abuse (< 20 g daily), evidence of hepatitis B and C, evidence of drug-induced fatty liver disease and other specific liver diseases such as hemochromatosis, Wilson's disease or autoimmune liver disease. The patients were assessed for metabolic syndrome, and biochemical, anthropometric and histopathological evaluations were carried out. The degree of disease activity in the NAFLD patients was evaluated using the NAFLD Activity Score. The data were analyzed by SPSS, version 16.0. RESULTS: Females predominated among the study participants (250, 57.0%), and the mean age was 40.8 +/- 10.2 years. The numbers of overweight, obese I and obese II patients were 58 (13.2%), 237 (53.9%) and 93 (21.2%), respectively. However, there were 422 (96.2%) centrally obese patients. NASH was absent in 10 (5.6%) cases, borderline in 92 (52.6%) cases and present in 75 (42.4%) cases. The presence of diabetes could significantly (P = 0.001) differentiate NASH from simple steatosis. The following parameters did not influence the development of NASH: age, sex, basal metabolic index, waist circumference, serum high-density lipoprotein, triglyceride, insulin resistance index, hypertension and metabolic syndrome. The serum gammaglutamyl transpeptidase (GGT) level was significantly higher (P = 0.05, 51.7 +/- 32.8 and 40.4 +/- 22.6 U/L) in the NASH patients, with a sensitivity of 45% and a specificity of only 68%. The serum alanine aminotransferase and aspartate aminotransferase levels were not able to predict NASH. CONCLUSION: Females were the predominant sufferers of NAFLD in Bangladesh. The prevalence of NASH was high. Diabetes was found to be the main culprit in developing NASH. GGT was the only biochemical marker of NASH. We recommend liver biopsy in NAFLD patients who have diabetes and elevated GGT. (C) 2013 Baishideng. All rights reserved.
引用
下载
收藏
页码:281 / 287
页数:7
相关论文
共 50 条
  • [41] The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Shouhed, Daniel
    Steggerda, Justin
    Burch, Miguel
    Noureddin, Mazen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (09) : 797 - 811
  • [42] Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
    Radwan, Mohamed M.
    Radwan, Basil M.
    Nandipati, Kalyana C.
    Hunter, William J., III
    Agrawal, Devendra K.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (08) : 727 - 738
  • [43] The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Cha J.-Y.
    Kim D.-H.
    Chun K.-H.
    Laboratory Animal Research, 2018, 34 (4) : 133 - 139
  • [44] Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Beaton, Melanie D.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 26 (06) : 353 - 357
  • [45] Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children
    Kleiner, David E.
    Makhlouf, Hala R.
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 293 - +
  • [46] The spectrum of nonalcoholic fatty liver disease: From steatosis to nonalcoholic steatohepatitis
    Saadeh, S
    Younossi, ZM
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2000, 67 (02) : 96 - +
  • [47] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [48] Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Younossi, Zobair M.
    Henry, Linda
    Bush, Haley
    Mishra, Alita
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 1 - +
  • [49] CARDIOVASCULAR RISK FACTORS IN NONALCOHOLIC FATTY LIVER DISEASE/NONALCOHOLIC STEATOHEPATITIS
    Ivanova, R.
    Gospodinova, M.
    Petrova, J.
    Alexiev, A.
    Denchev, S.
    Mateva, L.
    ATHEROSCLEROSIS, 2014, 235 (02) : E240 - E240
  • [50] Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Takahashi, Yoshihisa
    Sugimoto, Keiichiro
    Inui, Hiroshi
    Fukusato, Toshio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (13) : 3777 - 3785